Sponsored by
Celldex presented impressive data at the SNO meeting last week. They had a 3.4 month survival advantage with recurrent GBM patients. That should be a large enough benefit to get FDA approval. They will wait until they have the results on more patients, and if it hold up to this level of benefit, will ask FDA for approval. This would be a tremendous benefit as it is a simple vaccine with minimal side effects.